FCB lands two DTC accounts

Share this article:
FCB was awarded the DTC advertising for Hoffman-LaRoche's two drugs, Pegasys and Copegus, that treat hepatitis C. Annual media spending for upcoming campaigns could exceed $30 million, sources said.
The agency, which is a unit of the Interpublic Group, pitched against three other undisclosed agencies.
Pegasys and Copegus were approved by the FDA two years ago, but this marks the first DTC campaign for both. The FDA has granted a six-month Priority Review Status to the supplemental new biologics license application (sBLA) for the combination therapy of Pegasys in combination with Copegus for the treatment of hepatitis C in patients who are also infected with HIV. Roche submitted this file with the FDA in August 2004.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.